Ask AI
Biomarker Testing in RR CLL

CE

When CLL Progresses: Interpreting Biomarker Testing Results and Planning the Next Step

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.25 Nursing contact hour, including 0.25 hour of pharmacotherapy credit

Released: June 05, 2026

Expiration: December 04, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Based on recent clinical trial data and guideline updates, which of the following would be the most accurate to tell a patient about the current FDA-approved indication of pirtobrutinib in CLL/SLL?

2.

A 72-year-old patient with CLL previously received fixed-duration venetoclax plus rituximab and achieved a 3-year remission. The patient now has progressive lymphadenopathy and rising lymphocyte count meeting criteria for treatment. The patient is referred for biomarker testing. 

 How would you explain the rationale for biomarker testing to a patient?